MOUNTAIN VIEW, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath$(R)$ , a patented, FDA-cleared drug-delivery device, today announced the formation of a dedicated RenovoCath Medical Advisory Board ("MAB") to support its clinical and strategic initiatives.

The MAB brings together leading US interventional radiology experts to provide strategic clinical insights that further advance the TAMP (Trans-Arterial Micro-Perfusion) therapy platform in clinical indications of high unmet medical need. The MAB compliments the Company's esteemed and long-standing Scientific Advisory Board that provides specialized guidance on RenovoRx's scientific research and clinical program strategy.

The MAB will support RenovoRx's ongoing clinical and market strategy and provide important insights into potential investigator-initiated trials supported by the Company. These capital-efficient studies are designed to provide meaningful data that may further broaden the application for the TAMP platform. Enabled by the RenovoCath device, TAMP is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy. Current RenovoRx-supported investigator-initiated trials include borderline resectable and metastatic pancreatic cancer and could eventually lead to expansion of targeted indications.

The MAB will also provide feedback to RenovoRx's sales and marketing team as they work to bring RenovoCath to market as a standalone device within its FDA-cleared indications for use.

"The formation of the MAB marks an exciting milestone for RenovoRx, and we're honored to have such respected interventional radiology experts supporting advancement of the RenovoCath device," said Ramtin Agah, MD, RenovoRx's Chairman and Chief Medical Officer. "Their collective expertise will help guide real-world evidence generation as we advance our novel approach to localized, targeted drug delivery, aiming to improve outcomes for patients diagnosed with difficult-to-treat cancers."

Initial members of the MAB include:

   -- Dr. Nadine Abi-Jaoudeh, MD -- UCI Health | Orange County, CA Dr. 
      Abi-Jaoudeh serves as Chief of Interventional Radiology and Director of 
      Clinical Research in the Department of Radiology at the University of 
      California, Irvine as well as Deputy Editor of the Journal of Vascular 
      and Interventional Radiology. She is recognized for her leadership in 
      image-guided oncology and translational research. Her expertise includes 
      minimally invasive procedures including percutaneous ablations and 
      intra-arterial therapies, with a focus on advancing treatments in primary 
      and metastatic hepatobiliary pancreatic cancers. 
   -- Dr. Mustafa Al-Roubaie, MD -- Moffitt Cancer Center | Tampa, FL Dr. 
      Al-Roubaie has a clinical focus in interventional oncology and 
      embolotherapy and is an active investigator with experience in minimally 
      invasive approaches across both malignant and benign disease states. He 
      holds academic appointments as Associate Professor of Radiology and 
      Oncologic Sciences at the University of South Florida School of Medicine. 
   -- Dr. Khashayar Farsad, MD, PhD -- Oregon Health and Science University | 
      Portland, OR Dr. Farsad is the Josef Rosch Professor and Chair of the 
      Department of Interventional Radiology, Director of Dotter Interventional 
      Institute, and Director of Research. He is a Fellow of the Society of 
      Interventional Radiology and actively serves on committees through the 
      American Board of Radiology, the Society of Interventional Radiology, and 
      the American College of Radiology. Dr. Farsad's areas of clinical and 
      academic interest include interventional management of portal 
      hypertension, image-guided treatment of solid organ malignancies, and 
      endovascular venous reconstruction. 
   -- Dr. Ripal Gandhi, MD -- Baptist Health South Florida | Coral Gables, FL 
      Dr. Gandhi serves as a principal investigator in RenovoRx's 
      post-marketing Registry Study, which evaluates cancer treatment delivered 
      by RenovoCath to solid tumors. He is a leader in interventional oncology 
      and endovascular therapy with active clinical roles at Miami Cancer 
      Institute and Miami Cardiac & Vascular Institute. His expertise includes 
      minimally invasive treatments for both cancer and vascular disease, and 
      he has trained physicians worldwide while serving as program director and 
      faculty for leading interventional radiology conferences, including 
      Interventional Symposium on Endovascular Therapy and Clinical 
      Interventional Oncology. 
   -- Dr. Paula Marie Novelli, MD -- University of Pittsburgh Medical Center | 
      Pittsburgh, PA Dr. Novelli is a board-certified interventional 
      radiologist with extensive experience in advanced image-guided 
      procedures. She currently practices at University of Pittsburgh Medical 
      Center and is an investigator in RenovoRx's ongoing Phase III TIGeR-PaC 
      trial evaluating intra-arterial gemcitabine delivery in locally advanced 
      pancreatic cancer. 
   -- Dr. Jonathan Kessler, MD -- City of Hope Comprehensive Cancer Center | 
      Duarte, CA Dr. Kessler is the Chief of the Division of Interventional 
      Radiology at City of Hope, where he directs advanced interventional 
      therapies for solid tumors. He has served at City of Hope for over a 
      decade, with clinical expertise in ablation, embolization, and supportive 
      oncology interventions. 

About RenovoCath

Based on its FDA clearance, RenovoCath(R) is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to select sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use ("IFU"), please see: IFU-10004-Rev.-G-Universal-IFU.pdf.

About RenovoRx, Inc.

RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath(R), a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx's patented Trans-Arterial Micro-Perfusion (TAMP(TM)) therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy. RenovoRx's novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents.

RenovoRx is in the initial stages of actively commercializing its TAMP technology and FDA-cleared RenovoCath as a stand-alone device. In December 2024, RenovoRx announced the receipt of its first commercial purchase orders for RenovoCath devices, and for the first nine months of 2025, approximately $900,000 of revenues were generated from RenovoCath sales. Several customers have already initiated repeat orders in parallel to RenovoRx expanding the number of medical institutions initiating new RenovoCath orders, including several esteemed, high-volume National Cancer Institute-designated centers. To meet and satisfy the anticipated demand, RenovoRx will continue to actively explore further revenue-generating activity, either on its own or in tandem with a medical device commercial partner.

RenovoRx is also evaluating its novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, (known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA's 21 CFR 312 pathway. IAG utilizes RenovoCath, the Company's patented, FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.

The IAG combination product candidate, which is enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA.

For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X.

Cautionary Note Regarding Forward-Looking Statements

(MORE TO FOLLOW) Dow Jones Newswires

February 10, 2026 08:30 ET (13:30 GMT)